LEO Pharma And Japan Tobacco Enter Into License Agreement For Novel JAK inhibitor Drug Candidate
LEO Pharma A/S and Japan Tobacco Inc. (JT) (TSE:2914) announced today that the companies have entered into a license agreement, under which LEO Pharma will obtain exclusive rights to further develop, register and market JT’s experimental JAK inhibitor, JTE-052, for topical use in dermatological indications worldwide, excluding Japan where JT retains rights.
The compound, currently in phase I trials for topical treatment of inflammatory skin conditions, has the potential to become LEO Pharma’s new platform for developing multiple treatment options for various inflammatory skin conditions.
Kim Kjoeller, Senior Vice President, Global Development, LEO Pharma, said: “LEO Pharma is excited about the opportunities this deal offers. While it’s still early days, LEO Pharma hopes this deal can pave the way for a series of new, safe and effective therapies for patients living with skin conditions. JT’s innovative compound not only has the potential to become a best-in-class therapeutic agent for topical treatment of inflammatory skin diseases, but also to offer LEO Pharma an entirely new platform for developing future patient solutions,” and added:
“This deal is testament to LEO Pharma’s global partnering strategy, a key driver for success in our mission to help people achieve healthy skin. By partnering with pioneering companies like JT, an international company with an innovative pharmaceutical division, LEO Pharma aims to push the boundaries of dermatology care and deliver more treatment solutions that make a real difference to the lives of people with skin diseases.”
Muneaki Fujimoto, President of JT’s Pharmaceutical Business, said: “This partnership with LEO Pharma, the global dermatology leader, is a significant milestone in our vision to develop original and innovative therapies for patients around the world. Given LEO Pharma's scientific and clinical expertise, this partnership provides a strong validation of the potential for JTE-052 to become an important therapeutic advance for those affected by skin diseases."
Under the terms of the agreement, LEO Pharma will be responsible for clinical and commercial activities, including manufacturing, outside Japan. JT will receive an upfront payment, development and sales milestone payments as well as royalties based on product sales.
Contact LEO Pharma
Eva Juul Langlands, Corporate Communicatons Manager
Corporate Communications
LEO Pharma A/S
Ballerup: +45 7226 2059
E-mail: eva.langlands@leo-pharma.com
Ryohei Sugata, General Manager
Dmitry Krivtsov, Associate General Manager
Media and Investor Relations Division
Japan Tobacco Inc.
Tokyo: +81-3-5572-4292
E-mail: jt.media.relations@jt.com
Help employers find you! Check out all the jobs and post your resume.
The compound, currently in phase I trials for topical treatment of inflammatory skin conditions, has the potential to become LEO Pharma’s new platform for developing multiple treatment options for various inflammatory skin conditions.
Kim Kjoeller, Senior Vice President, Global Development, LEO Pharma, said: “LEO Pharma is excited about the opportunities this deal offers. While it’s still early days, LEO Pharma hopes this deal can pave the way for a series of new, safe and effective therapies for patients living with skin conditions. JT’s innovative compound not only has the potential to become a best-in-class therapeutic agent for topical treatment of inflammatory skin diseases, but also to offer LEO Pharma an entirely new platform for developing future patient solutions,” and added:
“This deal is testament to LEO Pharma’s global partnering strategy, a key driver for success in our mission to help people achieve healthy skin. By partnering with pioneering companies like JT, an international company with an innovative pharmaceutical division, LEO Pharma aims to push the boundaries of dermatology care and deliver more treatment solutions that make a real difference to the lives of people with skin diseases.”
Muneaki Fujimoto, President of JT’s Pharmaceutical Business, said: “This partnership with LEO Pharma, the global dermatology leader, is a significant milestone in our vision to develop original and innovative therapies for patients around the world. Given LEO Pharma's scientific and clinical expertise, this partnership provides a strong validation of the potential for JTE-052 to become an important therapeutic advance for those affected by skin diseases."
Under the terms of the agreement, LEO Pharma will be responsible for clinical and commercial activities, including manufacturing, outside Japan. JT will receive an upfront payment, development and sales milestone payments as well as royalties based on product sales.
Contact LEO Pharma
Eva Juul Langlands, Corporate Communicatons Manager
Corporate Communications
LEO Pharma A/S
Ballerup: +45 7226 2059
E-mail: eva.langlands@leo-pharma.com
Ryohei Sugata, General Manager
Dmitry Krivtsov, Associate General Manager
Media and Investor Relations Division
Japan Tobacco Inc.
Tokyo: +81-3-5572-4292
E-mail: jt.media.relations@jt.com
Help employers find you! Check out all the jobs and post your resume.